ArticleInternational journal of molecular medicine2022

Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors.

Nunghathai Sawasdee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.